Hepaxane

Hepaxane is a prescription anticoagulant that contains the active ingredient enoxaparin sodium, a low‑molecular‑weight heparin. It is supplied as an injectable solution for intravenous, intra‑arterial, or hemodialysis administration. Hepaxane works by enhancing antithrombin III activity, which inhibits clotting factors Xa and IIa, thereby reducing the risk of thrombus formation. It is marketed in the European Union. It is indicated for several clinical situations where anticoagulation is required.

Hepaxane is used in medical practice to prevent and treat clot‑related conditions.

- Prevention of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism, in patients undergoing surgery or immobilization. - Treatment of acute venous thromboembolism to reduce clot propagation. - Anticoagulation during hemodialysis procedures to maintain circuit patency. - Adjunctive therapy in acute coronary syndromes when combined with other antiplatelet agents. - Prophylaxis of clot formation in patients receiving intra‑arterial interventions. - Management of patients with unstable angina undergoing percutaneous coronary intervention to reduce procedural thrombotic risk.

Like other low‑molecular‑weight heparins, Hepaxane may be associated with a range of adverse effects.

Common: - Minor bleeding at the injection site or bruising. - Small increases in activated partial thromboplastin time (aPTT) without clinical significance. - Nausea or mild gastrointestinal discomfort. - Elevated liver enzymes observed in routine monitoring. - Transient elevations in serum potassium levels that resolve after discontinuation. - Mild headache or dizziness reported by some patients.

Serious: - Major bleeding, including gastrointestinal or intracranial hemorrhage. - Thrombocytopenia, particularly heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as rash, itching, or anaphylaxis. - Spinal or epidural hematoma when used in patients receiving neuraxial anesthesia.

Precautions for Hepaxane focus on bleeding risk, patient monitoring, and specific clinical situations.

- Assess baseline coagulation status and platelet count before initiating therapy. - Use caution in patients with active gastrointestinal ulcers, recent surgery, or trauma. - Adjust dose or avoid use in severe renal impairment (creatinine clearance <30 mL/min). - Monitor for signs of bleeding, including hematuria, melena, or unexplained bruising. - Avoid concurrent use with other anticoagulants or antiplatelet drugs unless medically justified. - Consider pregnancy status; limited data are available, so risk‑benefit assessment is essential. - Discontinue Hepaxane prior to invasive procedures and resume only when hemostasis is secured.

Hepaxane can interact with other medicines that affect hemostasis or renal function, potentially altering its anticoagulant effect.

Avoid: - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) due to heightened bleeding risk. - Combination with potent antiplatelet agents such as clopidogrel or ticagrelor without close monitoring. - Co‑administration with high‑dose aspirin exceeding 300 mg daily. - Avoid use with systemic thrombolytics such as alteplase unless absolutely necessary.

Use with caution: - NSAIDs or corticosteroids, which may increase gastrointestinal bleeding. - Renal‑clearing drugs (e.g., aminoglycosides, contrast agents) in patients with impaired kidney function. - Thrombolytic therapy or fibrinolytics, requiring careful assessment of bleeding risk.